FibroGen Inc (FGEN)
1.125
-0.04
(-3.02%)
USD |
NASDAQ |
May 02, 16:00
1.125
0.00 (0.00%)
After-Hours: 20:00
FibroGen Enterprise Value: -7.110M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 01, 2024 | -7.110M |
April 30, 2024 | -11.06M |
April 29, 2024 | -14.02M |
April 26, 2024 | -18.96M |
April 25, 2024 | -20.94M |
April 24, 2024 | -24.46M |
April 23, 2024 | -16.00M |
April 22, 2024 | -9.086M |
April 19, 2024 | -8.098M |
April 18, 2024 | -6.123M |
April 17, 2024 | 3.754M |
April 16, 2024 | 6.718M |
April 15, 2024 | 7.705M |
April 12, 2024 | 6.718M |
April 11, 2024 | 12.64M |
April 10, 2024 | 19.56M |
April 09, 2024 | 27.46M |
April 08, 2024 | 39.31M |
April 05, 2024 | 38.32M |
April 04, 2024 | 34.37M |
April 03, 2024 | 23.51M |
April 02, 2024 | 91.66M |
April 01, 2024 | 111.42M |
March 28, 2024 | 110.43M |
March 27, 2024 | 133.14M |
Date | Value |
---|---|
March 26, 2024 | 119.32M |
March 25, 2024 | 139.07M |
March 22, 2024 | 133.14M |
March 21, 2024 | 118.33M |
March 20, 2024 | 111.42M |
March 19, 2024 | 110.43M |
March 18, 2024 | 92.65M |
March 15, 2024 | 84.75M |
March 14, 2024 | 84.75M |
March 13, 2024 | 75.86M |
March 12, 2024 | 64.99M |
March 11, 2024 | 47.21M |
March 08, 2024 | 56.10M |
March 07, 2024 | 55.12M |
March 06, 2024 | 63.02M |
March 05, 2024 | 68.94M |
March 04, 2024 | 73.88M |
March 01, 2024 | 59.07M |
February 29, 2024 | 47.21M |
February 28, 2024 | 74.38M |
February 27, 2024 | 87.71M |
February 26, 2024 | 61.04M |
February 23, 2024 | 58.08M |
February 22, 2024 | 64.99M |
February 21, 2024 | 47.71M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-145.12M
Minimum
Sep 22 2023
4.434B
Maximum
Feb 12 2021
1.633B
Average
1.352B
Median
Enterprise Value Benchmarks
Annovis Bio Inc | 61.52M |
Emergent BioSolutions Inc | 849.25M |
Geron Corp | 1.973B |
Vertex Pharmaceuticals Inc | 92.67B |
Regulus Therapeutics Inc | 141.24M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -56.23M |
Revenue (Quarterly) | 27.14M |
Total Expenses (Quarterly) | 81.33M |
EPS Diluted (Quarterly) | -0.57 |
Gross Profit Margin (Quarterly) | 80.08% |
Profit Margin (Quarterly) | -207.2% |
Earnings Yield | -260.4% |
Normalized Earnings Yield | -251.43 |